Upload
zoe-mitchell
View
400
Download
2
Embed Size (px)
Citation preview
2015 ERS EVENTS
DATE: FRIDAY SEPTEMBER 25TH
VENUE: Wyndham Apollo Hotel, AmsterdamROOM: BoardroomTIME: 8:00-9.00AM
CHAIR: Jerry A. Krishnan, Professor of Medicine and Public Health & Associate Vice President for Population Health Sciences, University of Illinois Hospital & Health Sciences System, Chicago, Illinois, USA
PCORI GRANT PLANNING MEETING
Agenda
Alignment of REG & PCORI Missions• REG
o To integrate high-quality, real-life evidence into clinical practice guidelines, policy and budgetary decision-making for the benefit of all stakeholders in respiratory medicine.
o Through: building networks & partnerships, research, setting standards, raising knowledge and awareness
• Patient Centered Outcomes Research Institute (PCORI)o U.S. Affordable Care Act 2010; traditional medical research… hasn’t been able to
answer many of the questions that patients and their clinicians face daily…o Funds patient-centered comparative clinical effectiveness research and
disseminates the results in ways that the end-users will find useful and valuable
o Established a data infrastructure linking EHRs in operating heath systems that provides coverage for ~100M individuals in U.S. (PCORnet)
o Open to co-funding from stakeholders
Comparative Effectiveness Research
- conduct and synthesis of research comparing the benefits and harms of different interventions in “real world” settings.
- to improve health outcomes by developing and disseminating evidence-based information to patients, clinicians, and other decision-makers, responding to their expressed needs, about which interventions are most effective for which patients under specific circumstances. US Recovery Act Spend Plan, Office of the Secretary, DHHS,
2009
Our mandate is to improve the quality and relevance of evidence available to help patients, caregivers, clinicians, employers, insurers, and policy makers make informed health decisions.
PCORI funding opportunities3 cycles/y (Cycle 3: LOI due 11/2015 then application due 02/2016)
Total direct costs Improving methods for PCOR $750K, 3y Communication and dissemination $1.5M, 3y Improving Healthcare Systems $1.5, 3y to $5M, 5y Prevention, Dx, and Tx options $2M, 3y Addressing disparities $1.5M, 3y
Pragmatic clinical studies $15M, 5y
Cycle 1 LOI due 3/2016, application due 6/2016
Research application criteria
StakeholdersRoles Evidence prioritization
Evidence generation
Evidence synthesis
Evidence dissemination
Evidence implementation
Feedback for future efforts
Types1. Patients and caregivers2. Providers (clinicians,
delivery systems)3. Purchasers (e.g.,
employers)4. Payers (e.g., insurance) 5. Policymakers (federal,
state)6. Product makers (drug
and device manufacturer)
7. Principal investigators (researchers)
Cancannon T, JGIM 2012
Ideas…?• UK “State of the Union” – current asthma morbidity in the UK • Evaluation of the association between duration of antibiotic courses (for respiratory infections) and issuance of
repeat prescriptions • Development, Validation and Evaluation of a Short form of EXACT (Exacerbations of Chronic Pulmonary Disease
Tool) Questionnaire for Clinical Use and Self-(tele) Monitoring • Validation of the COPD UK Risk Prediction Model and development of a claims-based algorithm • Comparative effectiveness of triple (ICS/LABA/LAMA) vs dual therapy (ICS/LABA) in COPD • Development of a Longitudinal Asthma Treatment Step Algorithm and Association with Asthma Outcomes • Towards Optimum Reporting of Pulmonary Effectiveness Databases and Outcomes (TORPEDO) Checklist:
development of a quality checklist for respiratory research databases • Systematic review & meta-analyses of the effect of ICS particle size on real-life asthma outcomes • Metabolic and long-term implications of ICS particle size in obstructive lung disease • Intra and trans-database comparison of “research-ready” definitions of ACOS • Characterizing the primary care pathway to idiopathic pulmonary fibrosis (IPF) diagnosis – a UK database study • Global Characterization of ILD MDT Practice & Agreement and Accuracy of IPF diagnosis evaluation• Evaluating and describing current development practice of technology based solutions • Drawing on existing literature: how should health information be fed back to (positively) change patient
behaviour? • Optimising App interfaces for older people with chronic respiratory diseases • Implications of ICS cessation in COPD – a real-life study • Exploration of the role and associations between nasal and bronchial hyper-reactivity in allergic airways disease • Are COPD patients with serum eos < 2% on inhaled corticosteroids at an increased risk to develop pneumonia? • Role of FeNO as a biomarker in COPD • Comparative decline in FEV1 over time in patients receiving dual vs triple therapy for COPD
Other ideas• Patients often report being on too many medications
o De-escalation studieso Intermittent treatment escalation studies
• Patients have a difficult time remembering to use controllers or difficulty using inhaler deviceso Studies testing adherence promotion strategieso Studies testing strategies to improve inhaler technique (including
limiting the number of different inhaler devices)
• Asthma-COPD Overlap Syndrome
Technologies WG Agenda…?
Next steps
• Topic nomination
• Stakeholder engagemento Prioritize topics (analytic hierarchy process)
o Develop teams to develop different application(s) (PICOTS)
• Jerry Krishnan [email protected]